Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein

Cephalalgia

Volumn 35, Issue 2, 2015, Pages 182-189

  Labruijere, Sieneke ^a   Chan, Kayi Y ^a   De Vries, René ^a   Van Den Bogaerdt, Antoon J ^a   Dirven, Clemens M ^a   Danser, A H Jan ^a   Kori, Shashidhar H ^b   Van Den Brink, Antoinette Maassen ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Autonomic Technologies Inc   (United States)

Author keywords

5 HT; Dihydroergotamine; Human coronary artery; Migraine; Sumatriptan; Vasoconstriction

Indexed keywords

DIHYDROERGOTAMINE; SUMATRIPTAN; VASOCONSTRICTOR AGENT;

ARTERY CONSTRICTION; ARTICLE; BLOOD LEVEL; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MAXIMUM PLASMA CONCENTRATION; MENINGEAL ARTERY; MIDDLE MENINGEAL ARTERY; SAPHENOUS VEIN; ADOLESCENT; ADULT; AGED; CORONARY BLOOD VESSEL; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; VASOCONSTRICTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CORONARY VESSELS; DIHYDROERGOTAMINE; FEMALE; HUMANS; MALE; MENINGEAL ARTERIES; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; SAPHENOUS VEIN; SUMATRIPTAN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 84927768565     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414544977     Document Type: Article

References (33)

1. Edvinsson L, Villalón CM and Maassen Van Den Brink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012;136:319-333.
2. Baron EP and Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache 2010;50:1353-1361.
3. Dahlöf C and Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache 2012;52:707-714.
4. Silberstein SD and McCrory DC. Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache 2003;43:144-166.
5. Villalón CM and Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: A pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 2007;376:45-63.
6. Tfelt-Hansen PC and Koehler PJ. One hundred years of migraine research: Major clinical and scientific observations from 1910 to 2010. Headache 2011;51:752-778.
7. Maassen Van Den Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
8. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache 2011;51:507-517.
9. Silberstein S. MAP0004: Dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother 2012;13:1961-1968.
10. Cunningham M, De Torrente A, Ekoe JM, et al. Vascular spasm and gangrene during heparin-dihydro-ergotamine prophylaxis. Br J Surg 1984;71:829-831.
11. Chan KY, Labruijere S, Ramírez Rosas MB, et al. Cranioselectivity of sumatriptan revisited: Pronounced contractions to sumatriptan in small human isolated coronary artery. CNS Drugs 2014;28:273-278.
12. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet 1998;351:1165-1169.
13. Sun H, Mohri M, Shimokawa H, et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 2002;39:847-851.
14. Chan KY, De Vries R, Leijten FP, et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol 2009;619:61-67.
15. Mulvany MJ and Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;41:19-26.
16. Maassen Van Den Brink A, Van Den Broek RW, De Vries R, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000;55:1524-1530.
17. Maassen Van Den Brink A, Bax WA, Ramrattan NN, et al. Human isolated coronary artery contraction to sumatriptan: A post hoc analysis. Cephalalgia 1999;19:651-654.
18. Lesage AS, Wouters R, Van Gompel P, et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol 1998;123:1655-1665.
19. Leysen JE, Gommeren W, Heylen L, et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: Ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 1996;50:1567-1580.
20. Napier C, Stewart M, Melrose H, et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999;368:259-268.
21. Nilsson F, Nilsson T, Edvinsson L, et al. Effects of dihydroergotamine and sumatriptan on isolated human cerebral and peripheral arteries and veins. Acta Anaesthesiol Scand 1997;41:1257-1262.
22. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-184.
23. Hoskin KL, Kaube H and Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996;119:249-256.
24. Grande G, Labruijere S, Haanes KA, et al. Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. J Headache Pain 2014;15:22.
25. Maassen Van Den Brink A, Bax WA, Ferrari MD, et al. Augmented contraction of the human isolated coronary artery by sumatriptan: A possible role for endogenous thromboxane. Br J Pharmacol 1996;119:855-862.
26. Mehrotra S, Gupta S, Garrelds IM, et al. Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. Naunyn Schmiedebergs Arch Pharmacol 2006;374:163-175.
27. Halloul Z, Meyer F, Lippert H, et al. Ergotamineinduced acute vascular insufficiency of the lower limb - a case report. Angiology 2001;52:217-221.
28. Tepper SJ, Kori SH, Borland SW, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache 2012;52:37-47.
29. Ramanathan T and Skinner H. Coronary blood flow. CEACCP 2005;5:61-64.
30. Tfelt-Hansen PC. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review. Cephalalgia 2013;33:1122-1131.
31. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache 2008;48:355-367.
32. Lacey LF, Hussey EK and Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543-548.
33. Plosker GL and McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-651.